- Home
- LVLU vs EDSA Comparison
LVLU vs EDSA Comparison
Compare LVLU & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVLU
- EDSA
- Stock Information
- Founded
- LVLU 1996
- EDSA 2015
- Country
- LVLU United States
- EDSA Canada
- Employees
- LVLU N/A
- EDSA N/A
- Industry
- LVLU Catalog/Specialty Distribution
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- LVLU Consumer Discretionary
- EDSA Health Care
- Exchange
- LVLU Nasdaq
- EDSA Nasdaq
- Market Cap
- LVLU 18.4M
- EDSA 15.9M
- IPO Year
- LVLU 2021
- EDSA N/A
- Fundamental
- Price
- LVLU $3.62
- EDSA $2.11
- Analyst Decision
- LVLU Hold
- EDSA Strong Buy
- Analyst Count
- LVLU 2
- EDSA 2
- Target Price
- LVLU $15.00
- EDSA $13.00
- AVG Volume (30 Days)
- LVLU 323.5K
- EDSA 38.0K
- Earning Date
- LVLU 08-13-2025
- EDSA 08-08-2025
- Dividend Yield
- LVLU N/A
- EDSA N/A
- EPS Growth
- LVLU N/A
- EDSA N/A
- EPS
- LVLU N/A
- EDSA N/A
- Revenue
- LVLU $302,783,000.00
- EDSA N/A
- Revenue This Year
- LVLU N/A
- EDSA N/A
- Revenue Next Year
- LVLU $2.53
- EDSA N/A
- P/E Ratio
- LVLU N/A
- EDSA N/A
- Revenue Growth
- LVLU N/A
- EDSA N/A
- 52 Week Low
- LVLU $2.98
- EDSA $1.55
- 52 Week High
- LVLU $28.05
- EDSA $5.18
- Technical
- Relative Strength Index (RSI)
- LVLU 42.51
- EDSA 42.63
- Support Level
- LVLU $3.60
- EDSA $2.02
- Resistance Level
- LVLU $4.10
- EDSA $2.35
- Average True Range (ATR)
- LVLU 0.61
- EDSA 0.14
- MACD
- LVLU 0.05
- EDSA -0.03
- Stochastic Oscillator
- LVLU 32.66
- EDSA 18.00
About LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates majority of its revenue from customers based in the United States.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.